Oncogenic Fusions in Gliomas: An Institutional Experience
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00669806%3A_____%2F22%3A10443302" target="_blank" >RIV/00669806:_____/22:10443302 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216208:11140/22:10443302
Výsledek na webu
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=62TRz08_Iq" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=62TRz08_Iq</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.21873/anticanres.15671" target="_blank" >10.21873/anticanres.15671</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Oncogenic Fusions in Gliomas: An Institutional Experience
Popis výsledku v původním jazyce
Background/Aim: Gliomas are primary malignancies of the central nervous system (CNS). High-grade gliomas are associated with poor prognosis and modest survival rates despite intensive multimodal treatment strategies. Targeting gene fusions is an emerging therapeutic approach for gliomas that allows application of personalized medicine principles. The aim of this study was to identify detectable fusion oncogenes that could serve as predictors of currently available or newly developed targeted therapeutics in cross-sectional samples from glioma patients using next-generation sequencing (NGS). Patients and Methods: A total of 637 patients with glial and glioneuronal tumours of the CNS who underwent tumour resection between 2017 and 2020 were enrolled. Detection of fusion transcripts in FFPE tumour tissue was performed by a TruSight Tumour 170 assay and two FusionPlex kits, Solid Tumour and Comprehensive Thyroid and Lung. Results: Oncogene fusions were identified in 33 patients. The most common fusion was the KIAA1549-BRAF fusion, detected in 13 patients, followed by TACC3, FGFR3-Co5, FGFR3-AMBRA1), identified in 10
Název v anglickém jazyce
Oncogenic Fusions in Gliomas: An Institutional Experience
Popis výsledku anglicky
Background/Aim: Gliomas are primary malignancies of the central nervous system (CNS). High-grade gliomas are associated with poor prognosis and modest survival rates despite intensive multimodal treatment strategies. Targeting gene fusions is an emerging therapeutic approach for gliomas that allows application of personalized medicine principles. The aim of this study was to identify detectable fusion oncogenes that could serve as predictors of currently available or newly developed targeted therapeutics in cross-sectional samples from glioma patients using next-generation sequencing (NGS). Patients and Methods: A total of 637 patients with glial and glioneuronal tumours of the CNS who underwent tumour resection between 2017 and 2020 were enrolled. Detection of fusion transcripts in FFPE tumour tissue was performed by a TruSight Tumour 170 assay and two FusionPlex kits, Solid Tumour and Comprehensive Thyroid and Lung. Results: Oncogene fusions were identified in 33 patients. The most common fusion was the KIAA1549-BRAF fusion, detected in 13 patients, followed by TACC3, FGFR3-Co5, FGFR3-AMBRA1), identified in 10
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30103 - Neurosciences (including psychophysiology)
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2022
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Anticancer Research
ISSN
0250-7005
e-ISSN
1791-7530
Svazek periodika
42
Číslo periodika v rámci svazku
4
Stát vydavatele periodika
GR - Řecká republika
Počet stran výsledku
7
Strana od-do
1933-1939
Kód UT WoS článku
000778640800004
EID výsledku v databázi Scopus
2-s2.0-85127263366